Two issued U.S. grants are now on record. The public opening stays narrow by design: issued anchors, a public-safe portfolio map, and a clean path from brief to NDA diligence for a 10-family control architecture.
Public-safe summary only. Public records outrank page copy. The public surface stays narrow by design; deeper diligence begins only where fit is real.
Official surfacesCompany · Trust Center · Verify · Licensing · Legal
Public records outrank page copy. These issued grants are part of the public opening posture for the HALTSEAL / NOVACOV runtime-control lane.
Public record. Deeper diligence materials remain NDA-scoped.
Neural override verification and constraint architecture for sovereign AGI execution
Permit-before-action runtime control with fail-closed gating, short-lived permits, and immutable receipts.
Neural override verification and constraint architecture for sovereign AGI execution at driver, firmware, and hypervisor gateways
Lower-layer gateway enforcement for driver, firmware, and hypervisor control points.
The portfolio reads best as a control path — not as isolated claim sets.
Short-lived, audience-bound permits are minted only after freshness, inclusion, consistency, tier, quorum, and attestation predicates are satisfied.
Freshness, inclusion, and consistency checks verify the state that gates execution.
License set, quorum, and attestation predicates determine whether action may proceed.
Only PASS conditions produce a short-lived, audience-bound permit identifier.
Egress, device I/O, dispatch, or actuation require a valid permit before effect.
IAL entries and portable receipts preserve the evidence needed for independent review.
This is the control-rail thesis in plain language: verification lives inside the execution path before network egress, device I/O, dispatch, or actuation.
Architecture, not isolated claims.
The strategic read-through is strongest when the portfolio is shown as a governable control path from input to reliance.
TSIL, BAPR, NOVACOV / HALTSEAL, Gateway, ACE, HTI, ORPRG, TRC, PoPC, and RVAL2.
Input, runtime, compute, clinical or action gating, rendering, and reliance.
Clinical workflow gating and bedside finalization widen the stack into care delivery surfaces.
Issued anchor now on record, narrower public surface, broader depth available under NDA.
Authentic input and sensor-ingress control.
Bedside finalization and UI commit-boundary gating.
Runtime action control where output becomes action.
Lower-layer interception at driver, firmware, and hypervisor surfaces.
Compute admission with freshness, masks, and budget predicates.
Clinical workflow gating with permit-and-receipt semantics.
Commit-before-effect control at externalized boundaries.
Trusted rendering and output gating.
Receipt-anchored execution evidence and outcome validation.
Validator certification, conformance suites, and certifiable reliance.
Together these lanes form a governable architecture for input authenticity, bedside finalization, pre-action permissioning, compute admission, clinical workflow gating, effect-boundary control, trusted rendering, and proof-backed reliance.
The cleanest public opening is the runtime-action lane: issued U.S. anchors on record, a buyer-legible licensing path, and a narrower public surface. Broader control-stack depth remains available under NDA where fit is real.
Broader strategic process only makes sense when buyers read the bundle as architecture control, not isolated claims.
The public page is meant to be legible without over-disclosing claim detail, buyer-specific mapping, or diligence representations.
This page is informational only. Any patent license requires a separate written agreement.
No patent license by publication. We also avoid broad public ownership or encumbrance representations on this page. Relevant diligence representations are handled under NDA as applicable.
The story is not that patents exist. The story is that control sits where consequence begins.
This is a decisive control point for delegated execution, not another post-hoc monitoring surface.
Portable receipts, deterministic gating, and fail-closed behavior read more credibly than marketing language.
Serious buyers can inspect the public posture first, then go deeper only where the use case warrants it.
The portfolio compounds because adjacent lanes make each control point more strategic, not more random.
Short answers meant to reduce ambiguity while keeping the public surface disciplined.
No. Patent rights are not licensed by publication. Any patent license requires a separate written agreement.
A scoped set of relevant filings, claim sets, supporting materials, integration paths, and evidence expectations matched to your use case.
The public page is designed to be informative without over-disclosing claim detail, diligence materials, or buyer-specific integration depth.
Relevant diligence representations are handled under NDA as applicable. The public page avoids broader representations.
Start with the public-safe materials. If there is a real use case and a real review path, request the NDA package.
The public opening posture is now more concrete. The issued anchors make the runtime-action lane inspectable without expanding public disclosure beyond what belongs in the open.
Then go deeper only where diligence requires it.
To keep review clean and fast, include the items below in your first outreach.
